Ventrus Biosciences Inc Stock Nasdaq
Stocks
US9228221019
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 683M 585M 545M 500M 940M 65.32B 959M 6.47B 2.52B 32.74B 2.56B 2.51B 108B | P/E 2026 * |
-58.5x | P/E 2027 * | -11.5x |
|---|---|---|---|---|---|
| Enterprise Value | 683M 585M 545M 500M 940M 65.32B 959M 6.47B 2.52B 32.74B 2.56B 2.51B 108B | EV / Sales 2026 * |
11x | EV / Sales 2027 * | 21.2x |
| Free-Float |
72.34% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ventrus Biosciences Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Jason Okazaki
CEO | Chief Executive Officer | 50 | 2022-12-31 |
| Director of Finance/CFO | - | 2025-06-04 | |
Katie Kitrinos
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Altig
CHM | Chairman | 70 | 2026-06-03 |
Susan Mahony
BRD | Director/Board Member | 61 | 2017-12-13 |
John McHutchison
BRD | Director/Board Member | 68 | 2019-08-05 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.17% | +3.95% | +3.14% | +24.45% | 51.22B | |
| -1.36% | +4.82% | +485.55% | +614.84% | 45.38B | |
| -2.04% | +3.69% | +19.34% | +91.23% | 41.97B | |
| +2.72% | +6.02% | +33.33% | +19.66% | 42.15B | |
| 0.00% | -3.91% | +18.49% | +47.98% | 31.95B | |
| -1.85% | +3.48% | - | - | 16.73B | |
| +0.72% | +5.27% | +31.55% | +145.37% | 17.1B | |
| -0.82% | +2.53% | +6.21% | +34.34% | 14.76B | |
| +0.50% | +3.62% | +82.64% | +46.53% | 13.91B | |
| Average | -0.26% | +3.24% | +85.03% | +128.05% | 30.58B | |
| Weighted average by Cap. | -0.24% | +3.18% | +103.64% | +150.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 62.02M 53.1M 49.54M 45.46M 85.43M 5.93B 87.11M 588M 229M 2.97B 233M 228M 9.85B | 32.25M 27.61M 25.76M 23.64M 44.42M 3.09B 45.3M 306M 119M 1.55B 121M 118M 5.12B |
| Net income | -10.61M -9.09M -8.48M -7.78M -14.62M -1.02B -14.9M -101M -39.2M -509M -39.84M -38.98M -1.68B | -60.26M -51.6M -48.14M -44.17M -83.01M -5.77B -84.64M -571M -223M -2.89B -226M -221M -9.57B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
